High-Risk Early RCC May Benefit from Neoadjuvant Avelumab Plus Axitinib

Data from the NeoAvAx trial presented at 2022 ASCO GU show potential for neoadjuvant avelumab plus axitinib for high-risk, non-metastatic clear-cell renal cell carcinoma.

Results of the phase 2 NeoAvAx trial (NCT03341845) presented during the 2022 Genitourinary Cancers Symposium indicated that the neoadjuvant combination of avelumab (Bavencio) plus axitinib (Inlyta) has potential for use in…

Continue Reading

News Source: https://www.cancernetwork.com/view/high-risk-early-rcc-may-benefit-from-neoadjuvant-avelumab-plus-axitinib

Leave a comment

Your email address will not be published.